Fosamprenavir — разлика између измена
Изглед
Садржај обрисан Садржај додат
мНема описа измене |
|||
Ред 79: | Ред 79: | ||
| sec_combustion = |
| sec_combustion = |
||
}} |
}} |
||
'''Fosamprenavir''' je [[organsko jedinjenje]], koje sadrži 25 [[atom]]a [[ugljenik]]a i ima [[Молекулска маса|molekulsku masu]] od 585,607 [[Јединица атомске масе|-{Da}-]].<ref>-{Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008 Mar 28;5:5. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007 Nov-Dec;8(6):371-80. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Chapman TM, Plosker GL, Perry CM: Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64(18):2101-24. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A: Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Sension M: Initial therapy for human immunodeficiency virus: broadening the options. HIV Clin Trials. 2004 Mar-Apr;5(2):99-111. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT: Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98. {{cite journal|doi=|pmid=}}}-</ref><ref>-{Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68. {{cite journal|doi=|pmid=}}}-</ref><ref>{{cite journal|doi=|pmid=21059682}}</ref><ref>{{cite journal|doi=|pmid=18048412}}</ref> |
'''Fosamprenavir''' je [[organsko jedinjenje]], koje sadrži 25 [[atom]]a [[ugljenik]]a i ima [[Молекулска маса|molekulsku masu]] od 585,607 [[Јединица атомске масе|-{Da}-]].<ref>-{Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008 Mar 28;5:5. {{cite journal|doi=|pmid=18373851}}}-</ref><ref>-{Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007 Nov-Dec;8(6):371-80. {{cite journal|doi=|pmid=18042502}}}-</ref><ref>-{Chapman TM, Plosker GL, Perry CM: Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64(18):2101-24. {{cite journal|doi=|pmid=15341507}}}-</ref><ref>-{Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A: Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. {{cite journal|doi=|pmid=14982766}}}-</ref><ref>-{Sension M: Initial therapy for human immunodeficiency virus: broadening the options. HIV Clin Trials. 2004 Mar-Apr;5(2):99-111. {{cite journal|doi=|pmid=15116286}}}-</ref><ref>-{Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. {{cite journal|doi=|pmid=14693528}}}-</ref><ref>-{Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT: Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98. {{cite journal|doi=|pmid=12162471}}}-</ref><ref>-{Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68. {{cite journal|doi=|pmid=16485915}}}-</ref><ref>{{cite journal|doi=|pmid=21059682}}</ref><ref>{{cite journal|doi=|pmid=18048412}}</ref> |
||
== Osobine == |
== Osobine == |
||
Верзија на датум 17. јул 2023. у 05:15
![]() | |
![]() | |
Klinički podaci | |
---|---|
Prodajno ime | Lexiva, Telzir |
Drugs.com | Monografija |
Način primene | Oralno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 7,7 h |
Izlučivanje | Renalno, fekalno |
Identifikatori | |
CAS broj | 226700-79-4 ![]() |
ATC kod | J05AE07 (WHO) |
PubChem | CID 131536 |
DrugBank | DB01319 ![]() |
ChemSpider | 116245 ![]() |
ChEMBL | CHEMBL1664 ![]() |
Hemijski podaci | |
Formula | C25H36N3O9PS |
Molarna masa | 585,607 |
| |
|
Fosamprenavir je organsko jedinjenje, koje sadrži 25 atoma ugljenika i ima molekulsku masu od 585,607 Da.[1][2][3][4][5][6][7][8][9][10]
Osobine
Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 10 |
Broj donora vodonika | 4 |
Broj rotacionih veza | 14 |
Particioni koeficijent[11] (ALogP) | 2,4 |
Rastvorljivost[12] (logS, log(mol/L)) | -4,0 |
Polarna površina[13] (PSA, Å2) | 195,9 |
Reference
- ^ Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008 Mar 28;5:5. . PMID 18373851. Недостаје или је празан параметар
|title=
(помоћ) - ^ Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007 Nov-Dec;8(6):371-80. . PMID 18042502. Недостаје или је празан параметар
|title=
(помоћ) - ^ Chapman TM, Plosker GL, Perry CM: Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64(18):2101-24. . PMID 15341507. Недостаје или је празан параметар
|title=
(помоћ) - ^ Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A: Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. . PMID 14982766. Недостаје или је празан параметар
|title=
(помоћ) - ^ Sension M: Initial therapy for human immunodeficiency virus: broadening the options. HIV Clin Trials. 2004 Mar-Apr;5(2):99-111. . PMID 15116286. Недостаје или је празан параметар
|title=
(помоћ) - ^ Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. . PMID 14693528. Недостаје или је празан параметар
|title=
(помоћ) - ^ Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT: Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98. . PMID 12162471. Недостаје или је празан параметар
|title=
(помоћ) - ^ Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68. . PMID 16485915. Недостаје или је празан параметар
|title=
(помоћ) - ^ . PMID 21059682. Недостаје или је празан параметар
|title=
(помоћ) - ^ . PMID 18048412. Недостаје или је празан параметар
|title=
(помоћ) - ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ . PMID 11749573. Недостаје или је празан параметар
|title=
(помоћ) - ^ . PMID 11020286. Недостаје или је празан параметар
|title=
(помоћ)
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
![]() | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |